More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection
Alzheimer's patients could soon have more treatment options available. Biogen's Leqembi obtained approval from the U.S. Food and Drug Administration earlier this year, and another treatment from Eli Lilly, donanemab, may not be far behind.
The one drawback, however, is that those drugs treat Alzheimer's when the disease is in its early stages, and thus, many people won't be able to benefit from them. But there's a company that may solve that problem. Quest Diagnostics (NYSE: DGX) has a test that can help make it easier to assess the risk of developing Alzheimer's.
On July 31, Quest launched a direct-to-consumer blood test, AD-Detect, which assesses beta amyloid protein. Amyloid beta in the brain is often associated with Alzheimer's, and the test can identify whether there are abnormal levels, which can be crucial in identifying people who have a high risk of developing the disease.
Source Fool.com
Biogen Inc. Aktie
Die Biogen Inc. Aktie ist im Trend: Deutlich mehr Buy- als Sell-Einschätzungen.
Das Kursziel von 287 € für Biogen Inc. bedeutet eine deutliche Steigerung von über 50% gegenüber dem aktuellen Kurs von 184.5 €.
